SCHEMBL7094533

SCHEMBL7094533

COc1ccc(-c2cc(O[Si](C(C)C)(C(C)C)C(C)C)ccc2C(C)=O)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 5/20 0.46
NPC1 O15118 5/20 0.46
HPGD P15428 4/20 0.46
RAB9A P51151 4/20 0.46
TP53 P04637 2/20 0.46
BACE1 P56817 3/20 0.44
ALDH1A1 P00352 3/20 0.44
MAPK1 P28482 2/20 0.44
CYP3A4 P08684 1/20 0.44
CYP2C19 P33261 2/20 0.43
KDM4E B2RXH2 1/20 0.43
CYP1A2 P05177 1/20 0.43
CYP2D6 P10635 1/20 0.43
CYP2C9 P11712 1/20 0.43
STAT1 P42224 1/20 0.42
HSD17B10 Q99714 1/20 0.42
MAPT P10636 2/20 0.42
RECQL P46063 1/20 0.42
APP P05067 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6784673 0.88 BACE1 (0.42) SMN1; SMN2NPC1HPGDRAB9ABACE1
SCHEMBL2937610 0.81 MLLT1 (0.45) NPC1HPGDRAB9ATP53ALDH1A1
SCHEMBL7092176 0.78 FYN (0.40) SMN1; SMN2NPC1RAB9ATP53ALDH1A1
SCHEMBL5631648 0.76 MAPT (0.55) SMN1; SMN2HPGDRAB9ABACE1ALDH1A1
SCHEMBL5465425 0.76 TYK2 (0.42) HPGDRAB9ATP53ALDH1A1MAPK1
SCHEMBL22319299 0.75 ALDH1A1 (0.57) SMN1; SMN2NPC1HPGDRAB9ABACE1
SCHEMBL27542071 0.74 BACE1 (0.56) SMN1; SMN2NPC1HPGDRAB9ABACE1
SCHEMBL8853110 0.73 BACE1 (0.44) SMN1; SMN2HPGDBACE1ALDH1A1MAPK1
SCHEMBL1515687 0.71 GAA (0.63) SMN1; SMN2NPC1RAB9ABACE1ALDH1A1
SCHEMBL7591657 0.71 SMN1; SMN2 (0.75) SMN1; SMN2HPGDBACE1ALDH1A1CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030225132-A1 Heterocyclic salts such as 3-(3-Hydroxyphenyl)-2-(4-(2-(1-pyrrolidinium)ethoxyphenol)-2,3-dihydro-1,4 -benzoxathiin-6-ol hydrochloride salt, used as estrane agonists, for phrophylaxis of bone disorders DININNO FRANK P (US) 2003-12-04 US disclosed
WO-2003086388-A1 ESTROGEN RECEPTOR MODULATORS MERCK & CO., INC. (US) 2003-10-23 WO disclosed
WO-2003087073-A1 ESTROGEN RECEPTOR MODULATORS MERCK & CO., INC. (US) 2003-10-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030225132-A1 Heterocyclic salts such as 3-(3-Hydroxyphenyl)-2-(4-(2-(1-pyrrolidinium)ethoxyphenol)-2,3-dihydro-1,4 -benzoxathiin-6-ol hydrochloride salt, used as estrane agonists, for phrophylaxis of bone disorders GPER1, ESR2, ESR1 SMN1; SMN2 844/4885NPC1 840/4885HPGD 319/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.